The Prescription Drug Affordability Act would aim to stop pharmacy benefit managers, or PBMs, from “exploiting loopholes” to ...

Senate Study Bill 1051 would shield agricultural chemical companies like Bayer, which produces the glyphosate-based herbicide ...

--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics ... of abelacimab prompted the Independent Data Monitoring Committee to discontinue the study early. Results from AZALEA ...

A bill to stop Pharmacy Benefit Managers or PBMs from giving pharmacies less money than it costs to fill prescriptions advanced through the Iowa House Commerce Committee Tuesday. A bill to stop ...

they can make prescriptions more affordable for Americans and eliminate government waste in the American health care system by prioritizing pharmacy benefit manager (PBM) reform. A pharmacist is ...

Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...

Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Perspective Therapeutics (CATX – Research Report). The associated price target remains the same with $21.00. Justin Walsh ...

TransCode Therapeutics (RNAZ ... What To Know: The company’s Safety Review Committee approved the progression to the third cohort following a favorable review of safety and pharmacokinetic ...

The Knesset’s Cabinet Committee for Legislation approved MK Simcha Rothman’s bill on Sunday to replace the term "West Bank" with the historically accurate names "Judea and Samaria" in Israeli ...

The healthcare industry experienced a rollercoaster of a year in 2024, with pharmacy benefits undergoing significant shifts. Rising drug costs, advancements in medication technology, and changing ...

Coya Therapeutics, Inc. has Treg therapies for neurodegenerative and autoimmune diseases, targeting ALS, FTD, AD, and PD. However, their lead candidate is now clearly COYA 302. This drug basically ...

TG Therapeutics, Inc. (NASDAQ:TGTX) presented at the JP Morgan Healthcare Conference last week and CEO Michael Weiss used the time to talk about the accomplishments in 2024 and to provide fresh ...